SCHEMBL25923744

SCHEMBL25923744

C[C@@H]1CN(C(=O)OC(C)(C)C)[C@@H](c2ccc(F)cc2)CC1O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.41
RORC P51449 3/20 0.40
SLC6A3 Q01959 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NR1H2 P55055 3/20 0.37
NR1H3 Q13133 3/20 0.37
CACNA1H O95180 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD11B1 P28845 1/20 0.36
RIPK1 Q13546 1/20 0.36
SLC6A4 P31645 1/20 0.36
GPR119 Q8TDV5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31578439 1.00 TACR1 (0.41) TACR1RORCSLC6A3HDAC1HDAC2
SCHEMBL30551222 0.98 TACR1 (0.40) TACR1RORCSLC6A3HDAC1HDAC2
SCHEMBL29343647 0.88 NR1H2 (0.48) RORCNR1H2NR1H3KMT2ACYP1A2
SCHEMBL29327221 0.87 RIPK1 (0.48) TACR1RORCNR1H2NR1H3RIPK1
SCHEMBL29081839 0.87 RIPK1 (0.48) TACR1RORCNR1H2NR1H3RIPK1
SCHEMBL24364130 0.87 RIPK1 (0.48) TACR1RORCNR1H2NR1H3RIPK1
SCHEMBL29081840 0.87 RIPK1 (0.48) TACR1RORCNR1H2NR1H3RIPK1
SCHEMBL24365884 0.87 RIPK1 (0.48) TACR1RORCNR1H2NR1H3RIPK1
SCHEMBL31578365 0.85 TACR1 (0.42) TACR1RORCHDAC1HDAC2NR1H2
SCHEMBL25923745 0.85 TACR1 (0.42) TACR1RORCHDAC1HDAC2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN TACR1 310/4885RORC 486/4885SLC6A3 3935/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TACR1 23/4885RORC 586/4885SLC6A3 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.